Printer Friendly

Tyrosinemia type 1: an overview of nursing care.

Fumarylacetoacetate hydrolase (FAH) deficiency or tyrosinemia type 1 (TT1) is an inherited metabolic disease that can cause neurologic crisis and respiratory distress. An inborn error of metabolism, TT1 is a rare disease with a worldwide incidence of approximately one to two cases per 100,000 births, although in some populations, the incidence is much higher (Scott, 2006). It is a life-threatening disorder that is usually fatal before two years of age if not treated effectively. Larochelle et al. (1967) described TT1 in infants presenting with a painful neurologic disorder that was associated with ascites, liver failure, failure to thrive, coagulopathy, rickets, renal disease, and a cabbage-like odor. Since first described in the Canadian population, much has been learned about the disease. In the Saguenay Lac-St. Jean region of Quebec, Canada, the incidence is approximately one case per 1846 births (De Braekeleer & Larochelle, 1990; Paradis, 1996). There is reliable evidence that inborn errors of metabolism contribute to incidence of sudden infant death syndrome (SIDS), although actual numbers are difficult to quantify (Bennett & Rinaldo, 2001; Centers for Disease Control and Prevention [CDC], 2003; Hunt & Hauck, 2006).

Mandatory newborn screening saves lives, and diagnostic accuracy improves outcomes for children with TT1 (McHugh et al., 2011; Schunemann et al., 2008). When TT1 is identified by enhanced newborn screening methods, the disease is treatable (Turgeon et al., 2008). If not identified on newborn screening, children with the disease can present critically ill in metabolic acidosis. Children with inborn errors of metabolism are identified post-mortem when newborn screening fails to identify the disease in the neonate (Bennett & Rinaldo, 2001; CDC, 2003; Chace et al., 2001). Early identification and diagnosis are life-saving for these metabolically unstable patients. The pediatric nurse needs to understand the pathophysiology of the disease and nursing interventions that will improve patient outcomes to successfully intervene. An overview of the pathophysiology and nursing care will enhance outcomes when applied at the bedside.


TT1 is characterized by the child's inability to break down tyrosine. Tyrosine is an essential amino acid contained in protein that the body needs to perform cellular functions. Normally, the enzyme fumarylacetoacetate hydrolase (FAH) catalyzes tyrosine, but children with TT1 have a deficiency of this essential enzyme. The deficiency is caused by a mutation on chromosome 15q23-25 (Nyhan, Barshop, & Ozand, 2005; Paradis, 1996). The disease is an autosomal recessive disorder that is expressed when a child receives the trait or mutation from both parents. In the carrier state, the mutation is harmless but can be passed on to offspring.

An interruption in the tyrosine catabolic pathway causes a metabolic gridlock in the human body with toxic substances accumulating in tissues throughout the body. Treatment can prevent the accumulation of these toxic substances. The combination of improvements in newborn screening and pharmacotherapy has improved outcomes (Nobili et al., 2010).

The FAH enzyme at the terminal end of the tyrosine catabolic pathway is crucial to the breakdown of tyrosine. When it is absent, toxic metabolites higher up the pathway accumulate and cause disease (Scott, King, & Trahms, 2008). Occasionally, a spontaneous mutation can occur that produces pockets of normal enzyme activity, and this produces variable phenotypic expression (Nakamura, Tanaka, Mitsubuchi, & Endo, 2007). Because phenotypic expression varies, two children with the exact same chromosomal mutation can have varying degrees of disease severity.

FAH deficiency leads to an accumulation of fumarylacetoacetate, maleylacetoacetate, succinylacetoacetone, and succinylacetone. Maleylacetoacetate causes renal tubular dysfunction in a Fanconi-like syndrome of renal failure and vitamin D-resistant rickets (Jacobs, van Beurden, Klomp, Berger, & van den Berg, 2006). Fumarylacetoacetate and maleylacetoacetate cause hepatocyte injury that can result in end stage liver disease, bleeding, and hepatocellular carcinoma (Orejuela, Jorquera, Bergeron, Finegold, & Tanguay, 2008). Succinylacetone is an inhibitor of the heme synthesis pathway, causing neurotoxicity that is similar to lead poisoning or aminolevulinic acid dehydratase (ALAD) deficiency porphyria (Wyllie & Hyams, 2006). The neurotoxicity can cause muscle paralysis and respiratory arrest (Krous, 2010; Turgeon et al., 2008).


Newborn screening for TT1 is performed by tandem mass spectrometry. Tandem mass spectrometry is an accurate way to measure newborn blood spot specimens for the presence of disease markers. Each state mandates a different newborn screening panel for their population of newborns (Howell, 2009). Most states are now using the improved newborn screening test for TT1 that measures succinylacetone (Morrissey, Sunny, Fahim, Lubowski, & Caggana, 2011). Measurement of tyrosine is neither specific nor sensitive for the identification of TT1 (Allard, Grenier, Korson, & Zytkovicz, 2004). Succinylacetone measurement by tandem mass spectrometry is accurate and reliable for diagnosing TT1 in the newborn (Turgeon et al., 2008). Early identification of this life-threatening disease provides an opportunity to intervene prior to symptom onset.

The clinical presentation is complicated. Symptoms can be severe or chronic depending on phenotypic expression of the disease (Nakamura et al., 2007). Some children present with failure to thrive and poor growth, but others have an acute onset of metabolic acidosis, hepatomegaly, ascites, coagulopathy, and neurologic crisis (Croffie, Gupta, Chong, & Fitzgerald, 2010). Metabolic crisis is precipitated by hypoglycemia.


Children with TT1 must maintain strict metabolic control of their disease. Parents play a key role in metabolic control by maintaining dietary restriction of protein consumption and avoidance of protein catabolism (Ashorn, Pitkanen, Salo, & Heikinheimo, 2006). Typical treatment requires intensive developmentally appropriate patient and family education. An age-appropriate guide is useful to address these educational needs (see Table 1).

Avoiding protein catabolism is difficult in the presence of an acute viral illness. When unable to eat, the body naturally breaks down protein stores to maintain homeostasis. The breakdown of protein causes the level of amino acid tyrosine to rise and results in a metabolic crisis (Claudius, Fluharty, & Boles, 2005).

During fasting, the body produces ketones. Urine ketones can be used as a metabolic indicator of protein catabolism. Ketones are a breakdown product of fatty acid metabolism. Ketones in the urine should be managed as an emergency. When ketotic, it is essential for the child to consume glucose to prevent protein catabolism (Claudius et al., 2005). If the child is unable, intravenous therapy can prevent complications associated with increased tyrosine levels. An antiemetic may be ordered if nausea and vomiting are present. Antiemetics can also be prescribed as needed to prevent future episodes of ketosis and adverse outcomes (Fedorowicz, Jagannath, & Carter, 2011).

Without the steady consumption of fat and carbohydrates, muscle protein is metabolized and tyrosine levels rise. As tyrosine levels increase, toxic metabolites build up. One toxic metabolite is succinylacetone, which causes ALAD porphyria in a complex biochemical process that interferes with heme metabolism. This biochemical interaction results in neurologic crisis (Anderson et al., 2005).

Neurologic Crisis

Neurologic crisis can present as a syndrome of severe pain, paralysis, and respiratory arrest. Neurologic effects of FAH deficiency in TT1 include severe abdominal pain, extremity pain, nausea, vomiting, weakness, and altered level of conscious ness. Succinylacetone inhibits conversion of Delta-aminolevulinic acid to porphobilinogen in the heme synthesis pathway. Delta-aminolevulinic acid is neurotoxic. The symptoms are similar to the symptoms of porphyria. Lead is also an inhibitor of the conversion of Delta-aminolevulinic acid. Inhibition of the pathway causes neuropathy, neurologic crisis, paralysis, and respiratory distress (Mitchell et al., 1990). Mental retardation and seizure disorders have also been reported in children with errors in the metabolism of tyrosine (Palmer, 2006; Rocha et al., 2000). With careful medical management and nursing care, this complication is preventable. The ability to prevent neurologic deficits offers financial and ethical incentive to maintain high quality newborn screening for the disease (Bailey, Skinner, & Warren, 2005).

Neurologic crisis is preventable if the family is educated and health care providers respond appropriately to the metabolic crisis. The most important way to prevent neurologic crisis is prompt administration of IV glucose solutions, usually 10% or higher depending on severity of symptoms and serum glucose measurement. Arterial blood gas measurement with calculation of anion gap can indicate severity of metabolic acidosis. A written plan is advised for the family to have with them in the event of an emergency. The written emergency plan can advise providers of treatment plans and how to contact medical genetics experts for consultation. The American College of Emergency Physicians (ACEP) and the American Academy of Pediatrics (AAP) provide an online template that is useful in developing this document (AAP, 2010), which can be accessed online at form.pdf (ACEP, 2008).

Diet and Pharmacotherapy

TT1 is a treatable disease. An experienced team that includes a dietician, medical geneticist, advanced practice nurse, psychologist, school nurse liaison, and other practitioners will need to collaborate as an interdisciplinary team to enhance outcomes (Paradis, 1996). The treatment includes a low-protein diet with medical food or formula, as well as the medication nitisinone (Orfadin[R]). The orphan drug nitisinone is used to treat TT1. Nitisinone shifts the metabolic pathway for the catabolism of tyrosine (El-Karaksy et al., 2010). The recommended 1 to 2 mg/kg/day is divided into two daily doses and should be titrated until succinylacetone is undetected in the urine (AlDhalimy, Overturf, Finegold, & Grompe, 2002; D'Eufemia, Celli, Tetti, & Finocchiaro, 2011; McKiernan, 2006). It must be taken at least one hour before or two hours after a meal to promote complete absorption because food effect is unknown. It is available in 2, 5, and 10 mg capsules. For children unable to swallow capsules, the capsules can be opened and the contents suspended in a small amount of water, formula, or apple sauce immediately before use ("Nitisinone: New Drug ...," 2002).

One side effect of nitisinone observed during clinical trials was photophobia (eye irritation) related to elevated tyrosine levels. It is essential that the child remain on a low protein diet while taking nitisinone to prevent this complication (Kamboj, 2008; "Nitisinone: New Drug ...," 2002; Smith, 2008). Specific dietary recommendations are based on phenylalanine and tyrosine levels. The goal is to maintain serum phenylalanine above 20 to 30 pmole/L and serum tyrosine between 200 to 500 pM to prevent corneal opacities and cognitive delays (Scott et al., 2008). Medical food and supplemental low-protein foods can be ordered online with the assistance of a certified dietician who specializes in the management of children with inborn errors of metabolism. However, these foods are not always covered by health insurance plans (see Table 2). Chemistry scales for weighing medical food and low-protein cookbooks are also available from these companies.

Corneal opacities have been known to develop in some children taking nitisinone for TT1. It is highly recommended that plasma tyrosine levels be measured frequently, and slit lamp ophthalmology examinations performed yearly (Ahmad, Teckman, & Lueder, 2002). Corneal opacities have been associated with high plasma tyrosine levels; however, it is unclear if other factors may also contribute to this problem (Lock, Gaskin, Ellis, Provan, & Smith, 2006). To prevent this complication, tyrosine levels should be kept below 500 [micro]M.

Yearly electrocardiograms to monitor for interventricular septal hypertrophy and signs of cardiomyopathy are advised. This is a rare complication seen in some children with TT1. If signs of cardiomyopathy are detected, referral to a pediatric cardiologist is advised. Children treated early with nitisinone are less likely to develop cardiomyopathy (Arora, Stumper, Wright, Kelly, & McKiernan, 2006).

Tyrosine is also metabolized within the kidneys. Consultation with a pediatric nephrologist to monitor signs of tubular injury with resulting Fanconi syndrome is prudent. There is increased risk of renal carcinoma related to toxic metabolites. Nitisinone can decrease progression of renal disease (Santra, Preece, Hulton, & McKiernan, 2008). Measurement of cystatin C is a better indicator of renal function in the pediatric population (Westhuyzen, 2006). Growth delays and vitamin D-resistant rickets related to renal disease are common and usually improve with nitisinone therapy (Parri et al., 2006).

Liver Transplant

Decreased hepatocellular apoptosis in the presence of toxic metabolites in the liver increase the risk for hepatocellular carcinoma (HCC) in children with TT1. Consultation with a pediatric hepatologist and yearly ultrasounds, CT scans with contrast, or gadolinium-enhanced MRI can detect hepatic nodules early (Lauenstein et al., 2007). Alpha-fetoprotein (AFP) levels should be followed as well. Elevations of AFP may indicate HCC. Early referral for liver transplant before nodules are greater than 2 cm can be life-saving (Koelink et al., 2006).

Unfortunately, even with early nitisinone treatment, some children develop HCC and require liver transplant. After liver transplant, the new liver allograft provides FAH enzyme to metabolize dietary tyrosine. Post

transplant, the low-protein diet is unnecessary. The liver transplant team and pediatric hepatologists manage maintenance of immunosuppression. Liver transplant is considered life-saving, but it is not a cure for TT1. The risk of rejection, infection, and malignancy after liver transplant is significant (Arnon et al., 2011; Heffron et al., 2010).

Liver transplant decreases the tyrosine load, but it does not abolish renal exposure to the fumarylacetoacetate (FAA). Low-dose nitisinone can be used after liver transplant if succinylacetone is found in the urine. It is thought that low-dose nitisinone may slow nephropathy and decrease the risk of renal carcinoma from exposure to FAA and succinylacetone in the kidneys. The kidneys also metabolize tyrosine and may require transplant if end stage renal disease develops (Jacobs et al., 2006).

Nursing Care

The care of the child and family with TT1 requires an interdisciplinary, collaborative team approach. Following the tenets of family-centered care, the family is considered an essential part of the team and should be included in care planning in the acute care and outpatient care settings. At different stages of disease progression, treatment decisions will need to be made that enhance both the quantity and quality of life for the child and caregivers. The nurse assumes the role of patient advocate and educator to assure that the family participates in care planning and understands the chronic nature of this lifelong condition. Anticipatory guidance on immunizations, developmental milestones, and future therapy will enhance the quality of life (Vinson, 2002). Prior to transplant, the primary treatment is prevention of metabolic deterioration and neuro logic crisis with diet therapy and nitisinone. These therapies should be implemented in a developmentally appropriate way (see Table 2) (Miller & MacDonald, 2006; Taylor, 1996).

Growth and Development

Assessment of dietary intake by evaluation of a 24-hour food diary while on a low-protein diet is an important nursing intervention. A three-day dietary history can also provide critical information about the dietary challenges families face. A healthy diet within food restrictions will enhance normal growth and development. Growth measurements at routine visits should include height and weight measurements. Growth should be monitored by comparison to children of comparable age and gender with normalized values on standardized growth charts (Miller & MacDonald, 2006).

Children and families managing the strict diet will need detailed instructions and feedback on progress to be successful. An individualized nutritional assessment by the metabolic team will provide the dietary prescription, and nurses should educate families about specific measures that improve compliance. Careful attention to delivery of medical food in a socially and developmentally appropriate manner can make all the difference when compliance is an issue. The nursing goal is for the child to eventually self-manage the disease (Kieckhefer & Trahms, 2000; Kieckhefer, Trahms, Churchill, & Simpson, 2009). Co-management with family member supervision can be developed as early as two years of age and continue until the patient is able to self-manage his or her disease in adulthood. A table to outline the care and educational needs of the family at each developmental stage can be a useful tool when planning individualized care (see Table 1).

Patient and Family Education

Early recognition and management of complications to minimize the negative impact through appropriate care strategies will improve long-term outcomes. Minor viral illnesses can become serious if calories are not consumed. The catabolism of protein stores can induce a metabolic crisis. It is important for families of children with TT1 to be advised of this danger. They should be instructed in how to test the urine for ketones. Ketones in the urine can alert families to the danger.

Acute exacerbations should be managed in an acute care facility with close attention to glucose levels and monitoring for metabolic acidosis caused by a build up of toxic metabolites during fasting. Parents should be taught when to bring the patient to the hospital, when to consult the genetics team, and when to give Pedialyte[R] or glucose solutions to avoid this type of metabolic crisis (Claudius et al., 2005).

Infection prevention is important. Vaccine-preventable diseases can be avoided by routine vaccination to include yearly flu vaccines. After transplant, no live vims vaccines can be administered (Mack et al., 1996). Teaching families simple infection control, such as hand washing, can be helpful when developmentally appropriate.

Psychosocial Support

The complexity of disease management and variety of complications experienced by patients and their families make psychosocial supportive care and patient education essential. The psychosocial support of the family is a critically important role for the nurse. The nurse's role can minimize the impact of associated complications and delay disease progression. Support of the family and child can facilitate developmental achievement and allow the patient to live a happy and productive life. Green (2009). describes what it is like to manage a chronic disease that results in whole organ transplant. In an ethnographic design, Green (2009) isolated four key themes identified by parents of pediatric heart transplant recipients: coping with life, and constantly responsible, worried, and blessed. Parents of these children are under immense psychological pressure, but often feel blessed by the gift of a second chance at life for their child.

Coffey (2006) identified seven themes that describe how parents feel about parenting a child with a chronic disease. This metasynthesis reveals the complex emotions and hardship these families deal with on a daily basis. The seven themes revealed by this metasynthesis described parental feelings about survival as a family, the constant worry and struggles, the burden of disease and an attempt to take charge, critical periods during the illness, and bridges to the outside describing the isolation felt by some parents. Although parents often feel isolated and anxious, the nurse's role can provide critical emotional support, sensitivity to their struggle, education on technical care, and effective coping strategies that lighten their burden. Caring is truly the first step in assisting families dealing with the demands of managing a complicated disease such as TT1.

Acknowledgment: This work would not have been possible without the wise guidance of Dr. Karen Frith.

Statements of Disclosure: Please see page 67 for statements of disclosure.


America Academy of Pediatrics (AAP). (2010). Policy statement--Emergency information forms and emergency preparedness for children with special health care needs. Pediatrics, 125(4), 829-837.

American College of Emergency Physicians (ACEP). (2008). Emergency information form for children with special needs. Retrieved from http://www.acep. org/content.aspx?id=26276

Ahmad, S., Teckman, J.H., & Lueder, G.T. (2002). Corneal opacities associated with NTBC treatment. American Journal of Ophthalmology, 134(2), 266-268.

Al-Dhalimy, M., Overturf, K., Finegold, M., & Grompe, M. (2002). Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Molecular Genetics and Metabolism, 75(1), 38-45.

Allard, R, Grenier, A., Korson, M.S., & Zytkovicz, T.H. (2004). Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: Analysis of succinylacetone extracted from dried blood spots. Clinical Biochemistry, 37(11), 1010-1015.

Anderson, K., Bloomer, J., Bonkovsky, H., Kushner, J., Pierach, C., Pimstone, N., & Desnick, R. (2005). Recommendations for the diagnosis and treatment of the acute porphyrias. Annals of Internal Medicine, 142(2), 439-450.

Arnon, R., Annunziato, R., Miloh, T., Wasserstein, M., Sogawa, H., Wilson, M.....Kerkar, N. (2011). Liver transplan tation for hereditary tyrosinemia type I: Analysis of the UNOS database. Pediatric Transplantation, 15(4), 400-405.

Arora, N., Stumper, O., Wright, J., Kelly, D., & McKiernan, P. (2006). Cardiomyopathy in tyrosinaemia type I is common but usually benign. Journal of Inherited Metabolic Disease, 29(1), 54-57.

Ashorn, M., Pitkanen, S., Salo, M.K., & Heikinheimo, M. (2006). Current strategies for the treatment of hereditary tyrosinemia type I. Paediatric Drugs, 3(1), 47-54.

Bailey, D.B., Jr., Skinner, D., & Warren, S.F. (2005). Newborn screening for developmental disabilities: Reframing presumptive benefit. American Journal of Public Health, 95(11), 1889-1893.

Bennett, M.J., & Rinaldo, P. (2001).The metabolic autopsy comes of age (Editorial). Clinical Chemistry, 47(7), 1145-1146.

Centers for Disease Control and Prevention (CDC). (2003). Contribution of selected metabolic diseases to early childhood deaths - Virginia 1996-2001. Morbidity and Mortality Weekly Report, 52(29), 677-679. Retrieved from http://www. 5229a1.htm

Chace, D.H., DiPerna, J.C., Mitchell, B.L., Sgroi, B., Hofman, L.F., & Naylor, E.W. (2001). Electroscopy tandem mass spectrometry for analysis of acycarnitines in dried postmortem blood specimens collected ay autopsy from infants with unexplained cause of death. Clinical Chemistry, 47(7), 1166-1182.

Claudius, I., Fluharty, C., & Boles, R. (2005). The emergency department approach to newborn and childhood metabolic crisis. Emergency Medicine Clinics of North America, 23(3), 843-883.

Coffey, J.S. (2006). Parenting a child with chronic illness: A metasynthesis. Pediatric Nursing, 32(1), 51-59.

Croffie, J., Gupta, S., Chong, S., & Fitzgerald, J. (2010). Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. Pediatrics, 103(3), 675-768.

D'Eufemia, P, Celli, M.,Tetti, M., & Finocchiaro, R. (2011). Tyrosinemia type I: Long-term outcome in a patient treated with doses of NTBC lower than recommended. European Journal of Pediatrics, 170(6), 819-819.

De Braekeleer, M., & Larochelle, J. (1990). Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-LacSt-Jean. American Journal of Human Genetics, 47(2), 302-307.

El-Karaksy, H., Rashed, M., El-Sayed, R., El-Raziky, M., El-Koofy, N., El-Hawary, M., & Al-Dirbashi, O. (2010). Clinical practice. NTBC therapy for tyrosinemia type 1: How much is enough? European Journal of Pediatrics, 169(6), 689-693. doi:10. 1007/S00431-009-1090-1

Fedorowicz, Z., Jagannath, V.A., & Carter, B. (2011). Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database of Systematic Reviews, 7(9). doi:10.1002/ 14651858.CD005506.pub5

Green, N., Baily, M. A., Murray, T. H., Moyer, V., Teutsch, S. M., & Botkin, J. R. (2009). Every child is priceless: Debating effective newborn screening policy. Hastings Center Report, 39(1), 6-8.

Heffron, T.G., Pillen, T., Smallwood, G., Henry, S., Sekar, S., Solis, D., ... Romero, R. (2010). Liver retransplantation in children: The Atlanta experience. Pediatric Transplantation, 14(3), 417-425.

Howell, R.R. (2009). Every child is priceless: Debating effective newborn screening policy. The Hastings Center Report, 39(1), 4-6.

Hunt, C.E., & Hauck, F.R. (2006). Sudden infant death syndrome. Canadian Medical Association Journal, 174(13), 1861-1869.

Jacobs, S.M., van Beurden, D.H., Klomp, L.W., Berger, R., & van den Berg, I.E. (2006). Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity. Pediatric Research, 59(3), 365-370.

Kamboj, M. (2008). Clinical approach to the diagnoses of inborn errors of metabolism. Pediatric Clinics of North America, 55(5), 1113-1127.

Kieckhefer, G.M., & Trahms, C.M. (2000). Supporting development of children with chronic conditions: From compliance toward shared management. Pediatric Nursing, 26(4), 354-363.

Kieckhefer, G.M., Trahms, C.M., Churchill, S.S., & Simpson, J.N. (2009). Measuring parent-child shared management of chronic illness. Pediatric Nursing, 35(2), 101-108.

Koelink, C.J., van Hasselt, P, van der Ploeg, A., van den Heuvel-Eibrink, M.M., Wijburg, F.A., Bijleveld, C.M., & van Spronsen, F.J. (2006). Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer? Molecular Genetics and Metabolism, 89(4), 310-315.

Krous, H.F. (2010). Sudden unexpected death in infancy and the dilemma of defining the sudden infant death syndrome. Current Pediatric Reviews, 6(1), 5-12.

Larochelle, J., Mortezai, A., Belanger, M., Tremblay, M., Claveau, J.C., & Aubin, G. (1967). Experience with 37 infants with tyrosinemia. Canadian Medical Association Journal, 97(18), 1051-1054.

Lauenstein, T.C., Salman, K., Morreira, R., Heffron, T., Spivey, J.R., Martinez, E., ... Martin, D.R. (2007). Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: Center-based experience. American Journal of Roentgenology, 189(3), 663-670.

Lewis-Gary, M.D. (2001). Updates & kidbits. Transitioning to adult health care facilities for young adults with a chronic condition. Pediatric Nursing, 27(5), 521-524.

Lock, E.A., Gaskin, P., Ellis, M., Provan, W.M., & Smith, L.L. (2006). Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicology and Applied Pharmacology, 215(1), 9-16.

Mack, D.R., Chartrand, S.A., Ruby, E.I., Antonson, D.L., Shaw, B.W., Jr., & Heffron, T.G. (1996). Influenza vaccination following liver transplantation in children. Liver Transplantation and Surgery, 2(6), 431-437.

McHugh, D.M.S., Cameron, C.A., Abdenur, J.E., Abdulrahman, M., Adair, O., Al Nuaimi, S.A., ... Zakowicz, W.M. (2011). Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genetics in Medicine, 13(3), 230-254.

McKiernan, P.J. (2006). Nitisinone in the treatment of hereditary Trosinemia type 1. Drugs, 66(6), 743-750.

Miller, D., & MacDonald, D. (2006). Management of pediatric patients with chronic kidney disease. Pediatric Nursing, 32(2), 128-135.

Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H..... Larbisseau, A. (1990). Neurologic crises in hereditary tyrosinemia. The New England Journal of Medicine, 322(7), 432-437.

Morrissey, M.A., Sunny, S., Fahim, A., Lubowski, C., & Caggana, M. (2011). Newborn screening for Tyr-I: Two years' experience of the New York State program. Molecular Genetics and Metabolism, 103(2), 191-192.

Nakamura, K., Tanaka, Y., Mitsubuchi, H., & Endo, F. (2007). Animal models of tyrosinemia. The Journal of Nutrition, 137(6, Suppl. 1), 1556S-1560S.

"Nitisinone: New drug. Type 1 tyrosinemia. An effective drug." (2007). Prescrire International, 16(88), 56-58.

Nobili, V., Jenkner, A., Francalanci, P., Castellano, A., Holme, E., Callea, F., & Dionisi-Vici, C. (2010). Tyrosinemia type 1: Metastatic hepatoblastoma with a favorable outcome. Pediatrics, 126(1), e235-e238.

Nyhan, W.L., Barshop, B.A., & Ozand, P.T. (2005). Atlas of metabolic diseases. New York, NY: Oxford University Press.

Orejuela, D., Jorquera, R., Bergeron, A., Finegold, M.J., & Tanguay, R.M. (2008). Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. Journal of Hepatology, 48(2), 308-317.

Palmer, K.M. (2006). Abdominal pain due to acute intermittent porphyria: When is the sound of hoof-beats not horses, but zebras? A case report. Dimensions of Critical Care Nursing, 25(3), 103-109.

Paradis, K. (1996). Tyrosinemia: The Quebec experience. Clinical and Investigative Medicine, 19(5), 311-316.

Parri, N., Indolfi, G., Poggi, G., Donati, M.A., Gasperini, S., Procopio, E., & Resti, M. (2006). Liver disease and hypophosphatemic rickets: Suspect tyrosinemia TYPE-1. Digestive and Liver Disease, 38(10), A112-A113.

Rocha, M.E., Bandy, B., Costa, C.A., de Barros, M.P., Pinto, A.M., & Bechara, E.J. (2000). Iron mobilization by succinylacetone methyl ester in rats. A model study for hereditary tyrosinemia and porphyrias characterized by 5-aminolevulinic acid overload. Free Radical Research, 32(4), 343-353.

Santra, S., Preece, M., Hulton, S.A., & McKiernan, P. (2008). Renal tubular function in children with tyrosinaemia type I treated with nitisinone. Journal of Inherited Metabolic Disease, 31(3), 399-402.

Schunemann, J., Oxman, A., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G., ... Guyatt, G.H. (2008). GRADE: Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. British Medical Journal, 336, 1106-1110.

Scott, C.R. (2006). The genetic tyrosinemias. American Journal of Medical Genetics Part C (Seminars in Medical Genetics), 142C(2), 121-126.

Scott, C.R., King, L.S., & Trahms, C. (2008). Tyrosinemia type 1. Gene Reviews. Retrieved from http://www.ncbi.nlm.nih. gov/books/NBK1515/

Smith, M. (2008). Care of the infant with inherent metabolic disease. Paediatric Nursing, 20(4), 38-44.

Taylor, J.H. (1996). End stage renal disease in children: Diagnosis, management, and interventions. Pediatric Nursing, 22(6), 481-490.

Turgeon, C., Magera, M.J., Allard, P., Tortorelli, S., Gavrilov, D., Oglesbee, D., ... Matern, D. (2008). Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clinical Chemistry, 54(4), 657-664.

Vinson, J.A. (2002). Practice applications of research. Children with asthma: Initial development of the Child Resilience Model. Pediatric Nursing, 28(2), 149-158.

Westhuyzen, J. (2006). Cystatin C: A promising marker and predictor of impaired renal function. Annals of Clinical and Laboratory Science, 36(4), 387-394.

Wyllie, R., & Hyams, J.S. (2006). Pediatric gastrointestinal and liver disease pathophysioiogy/diagnosis/management. Philadelphia: Saunders Elsevier.

Additional Readings

Eggenhofer, E., Doenecke, A., Renner, P, Slowik, R, Piso, P, Geissler, E.K., ... Popp, F.C. (2010). High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. Journal of Gastroenterology and Hepatology, 25(5), 1002-1008.

Heffron, C. (2005). A perfect fit: Blending the roles of teacher and nurse. Association of Women's Health, Obstetric, and Neonatal Nurses Lifelines, 9(3), 272, 271.

Paulk, N.K., Wursthorn, K., Wang, Z., Finegold, M.J., Kay, M.A., & Grompe, M. (2010). Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology, 51(4), 1200-1208.

Rasko, J.E.J. (2010). A gene therapy renaissance? Journal of Gastroenterology and Hepatology, 25(5), 848-850.

Elizabeth Barnby, DNP, ACNP-BC, RN, is a Clinical Assistant Professor and Undergraduate Program Director, University of Alabama Huntsville, Huntsville, AL.
Table 1.
Age-Appropriate Care and Educational Needs of Children
with TTI and Families

                  Developmentally Appropriate Disease
Age of            Management Timeline for Nursing
Patient           Education of Caregivers and Patient

0 to 6 months     * Caregivers learn to prepare prescribed
                    formula using chemistry scale.

                  * Caregivers learn to complete 24-hour
                    diet history for review with dietician
                    and medical geneticist.

                  * Caregivers learn disease management
                    and pathophysiology of protein
                    metabolism in patient with TT1.

                  * Caregivers learn of financial
                    resources to purchase medical food
                    (varies by state and insurance).

                  * Caregivers learn importance of not
                    showing signs of aversion to medical
                    food since feeding is easily influenced
                    by social situations.

                  * Medical food is life-sustaining and
                    must be a positive social experience to
                    promote future healthy dietary habits.

                  * Caregivers learn to schedule
                    appointments with dietician every three

                  * Caregivers learn to notify health care
                    providers of episodes of ketosis
                    (inability to consume calories can
                    result in protein overdose when protein
                    catabolism occurs).

                  * Caregivers verbalize how protein
                    catabolism can cause toxic metabolites
                    to increase and become life threatening.

                  * Caregivers are given written emergency
                    action plan to carry at all times to
                    advise emergency providers of genetic
                    provider contacts and emergency care of
                    a child with TT1.

                  * Caregivers learn to schedule yearly
                    eye examinations to rule out tyrosine
                    accumulation in corneas.

                  * Caregivers administer Orfadin[R] as
                    prescribed (Orfadin[R] must be

6 months          * Caregivers introduce low-protein

                  * Caregivers learn to use books to look
                    up protein content of all foods and
                    enter on diet history record.

                  * Caregivers learn to meet exact protein
                    requirements (varies by weight and
                    medical food prescription).

                  * Caregivers learn to facilitate
                    consumption of exact protein

                  * Caregivers given low-protein cookbook,
                    and introduced to online sources of
                    low-protein foods and parent support

                  * Caregivers learn safe blood levels of

                  * Caregivers learn to prevent ketosis.

                  * Caregivers learn to measure ketones in
                    urine and act appropriately to reverse
                    ketosis with glucose solution or medical
                    intervention as needed.

6 to 7 months     * Caregivers introduce cup for
                    low-protein formula as prescribed.

8 to 9 months     * Caregivers introduce finger food
                    within specific protein restriction.

10 to 15 months   * Caregivers consider weaning to cup;
                    continue medical food as prescribed by

                  * Caregivers learn to prepare
                    low-protein meals.

                  * Siblings may assist with low-protein
                    diet preparation if interested.

2 to 3 years      * Patient learns to distinguish
                    acceptable foods.

                  * Patient begins to learn to swallow
                    capsule as tolerated.

4 to 5 years      * Patient learns to count foods.

                  * Patient begins to learn to weigh
                    medical food and other low-protein foods
                    on chemistry scales.

                  * Begins to measure grams of medical
                    food and assist with mixing of medical

5 to 6 years      * Patient assists caregivers with
                    formula preparation.

                  * Caregivers teach child how to interact
                    with other school-age children and
                    satisfy their curiosity about specific
                    dietary restrictions in a positive way.

                  * Caregivers teach educators to monitor
                    diet at school and prevent socially
                    inappropriate behaviors that inhibit
                    healthy diet habits.

7 to 10 years     * Patient begins to list foods on
                    14-hour diet recall.

                  * Patient learns to pack school lunch
                    with parental assistance.

                  * Patient chooses appropriate
                    afterschool snacks.

                  * Patient learns to look up protein
                    grams and read labels of foods.

                  * Patient learns to request restaurant
                    menus with protein content when

10 to 12 years    * Patient begins to prepare and consume
                    medical food independently with parental

                  * Patient learns to prepare simple
                    entrees with parental supervision.

                  * Patient learns safe blood levels of
                    tyrosine (below 500).

                  * Patient learns to plot height and
                    weight during clinic visits.

                  * Patient learns why height and weight
                    is important for overall health and

                  * Patient attends yearly metabolic camp
                    if available through referral in
                    genetics clinic. (Children with TT1
                    usually can attend metabolic camp with
                    children that have PKU since disease
                    management is similar.)

                  Developmentally Appropriate Disease
                  Management Timeline for Nursing
                  Education of Caregivers and Patient 1

Age of Patient    * This is merely a guide that should be
                    adjusted according to parent-child
                    shared management preferences.

13 to 14 years    * Patient learns menu planning.

                  * Patient expands on preparation of
                    meals with parental supervision.

                  * Patient keeps calendar for blood

                  * Patient assumes responsibility for
                    food records.

                  * Patient assists with grocery shopping
                    for appropriate low-protein foods.

                  * Patient attends low protein cooking
                    classes with peers with similar
                    low-protein diet needs.

                  * Patient learns to shop for low-protein
                    foods online and in person if available.

                  * Patient learns to interact with health
                    care providers with autonomy.

15 to 17 years    * Patient assumes responsibility for
                    remembering recent lab results.

                  * Patient schedules clinic appointments.

                  * Patient schedules yearly eye exams to
                    rule out tyrosine accumulation in

18 years          * Patient transition to adult clinic

                  * Patient manages diet and follow-up

                  * Patient learns to access assistance
                    when needed.

** If liver transplant is performed, diet therapy is
no longer necessary.

Sources: Kieckhefer & Trahms, 2000; Kieckhefer et al., 2009;
Lewis-Gary, 2001.

Table 2.
Medical Food and Formula Resource List

                                      Tyrosinemia      Low-Protein
Company Name          Contact           Formula            Foods

Cambrooke          508.782.2300                           Breads
Foods[R]             orders @                              Pasta
                     cambrooke                            Baking
                      http://                           Ready Meals
                     Cambrooke                            Cheese
                                                         Soups and

Mead              1.847.832.2420      Formula Per
Johnson[R]          http://www.      prescription
            and dietician
                  1.812.429.5000      management

Abbott            1.800.227.5767      Formula Per
Nutrition          http://Abbott     prescription
              and dietician

Nutricia          1.800.365.7354                        Baking mix
Advanced            Myspecial-                            Cereal
Medical                                Crackers
Nutrition         1.877.636.2283                           Pasta
LoProfin                                                 Cake mix

Applied           http://medical-                         Snacks
Nutrition                                Candy
                  1.800.605.0410                           Chips
                  1.973.734.0023                       Baking mixes

Dietary             http://www.                        Egg replacer
Specialties                           Breads
                                                       Peanut butter

Med Diet Lab                           Soups
                  1.736.550.2020                          Sauces
                    http://www.                            Mixes
COPYRIGHT 2014 Jannetti Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Continuing Nursing Education
Author:Barnby, Elizabeth
Publication:Pediatric Nursing
Article Type:Report
Date:Mar 1, 2014
Previous Article:Pot for tots: children and medical marijuana.
Next Article:Parenting efficacy and its relationship to the prevention of childhood obesity.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |